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Since the incorporation of tyrosine kinase inhibitors into the treatment of Philadelphia chromosomeepositive
(Phþ) acute lymphoblastic leukemia (ALL), the notion that all patients with “high-risk” ALL uniformly require
allogeneic (allo) hematopoietic cell transplantation (HCT) has received increasing scrutiny. Although multiple
studies have shown superiority of alloHCT over autologous (auto) hematopoietic cell transplantation for high-
risk patients, these ﬁndings may be explained, in part, by contamination of the peripheral blood progenitor
cell (PBPC) leukapheresis product by residual leukemic cells in patients undergoing autoHCT. We retro-
spectively evaluated minimal residual disease (MRD) using next-generation sequencing (NGS) in the PBPC
leukapheresis product of 32 ALL patients who underwent autoHCT. Twenty-eight patients (88%) had diag-
nostic samples with quantiﬁable immunoreceptor rearrangements to follow for MRD. Twelve (38%) patients
had Phþ B-ALL, 12 (38%) had Philadelphia chromosomeenegative (Ph) B-ALL, and 4 (14%) had T cell ALL.
With a median follow-up of 41 months (range, 3 to 217), median relapse-free survival (RFS) and overall
survival for the entire cohort were 3.2 and 4.2 years, respectively; at 5 years after transplantation, 42% of
patients remain alive and relapse free. Using MRD detection at a threshold of  1  106, median RFS for
patients with detectable MRD was 6.5 months and was not reached for patients without detectable disease
(P ¼ .0005). In multivariate analysis, the only factor signiﬁcantly associated with relapse was the presence of
MRD 1  106 (odds ratio, 23.8; conﬁdence interval, 1.8 to 312.9; P ¼ .0158). Our ﬁndings suggest that NGS
for MRD detection can predict long-term RFS in patients undergoing autoHCT for high-risk ALL.
 2016 The American Society for Blood and Marrow Transplantation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a relatively
uncommon malignancy, with an estimated 6250 new cases
in 2015 and 1450 deaths [1]. Despite improvements in out-
comes for children with ALL, survival of adult patients with
ALL remains poor, despite high initial complete remissionedgments on page 1035.
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c-nd/4.0/).(CR) rates and an increasingly large pool of potential allo-
geneic hematopoietic cell donors [2-4]. Factors identifying
patients at high risk of relapse include older age, elevated
white blood cell count at diagnosis, speciﬁc cytogenetic
abnormalities, and the presence of minimal residual disease
(MRD) measured at various time points during therapy [5-9].
In general, patients with high-risk disease are recommended
for allogeneic (allo) hematopoietic cell transplantation (HCT)
in ﬁrst CR if they are transplantation-eligible and have a
suitable donor available [10]. For all other patients, multi-
agent chemotherapydin combinationwith a tyrosine kinase
inhibitor (TKI) if Philadelphia chromosome positive (Phþ)d
is the accepted standard of care.n. This is an open access article under the CC BY-NC-ND license (http://
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use of autologous (auto) HCT in comparison with either
alloHCT or conventional chemotherapy alone for the
treatment of ALL [11-13]. More recent studies, however, sug-
gest potentially comparable outcomes between alloHCT and
an “intensiﬁed” autoHCT for select high-risk patients, espe-
cially in those patients with Phþ ALL who are treated with a
TKI before and/or after autoHCT [14-17]. Achievement of an
MRD-negative statemayhelp identify those patientswho can
achieve long-term relapse-free survival (RFS) without
alloHCT,with the limitation thatMRDmonitoring is subject to
differences in applicability, sensitivity, and reproducibility
based on the speciﬁc MRD-monitoring technology utilized
[18-21]. Recently, identiﬁcation of leukemia-associated clonal
rearrangements in immunoglobulin (Ig) and T cell receptor
(TCR) genes using next-generation sequencing (NGS) were
shown to predict post-alloHCT relapse and survival in adult
ALL patients with a high positive predictive value [22]. Logan
et al. found that 93% of patients had leukemia-associated
Ig/TCR clonotypes amenable to quantiﬁcation by NGS,
with a threshold of MRD  104 before alloHCT resulting in
a hazard ratio of 7.7 for post-transplantation relapse.
We hypothesized that a similar application of NGS to
identify MRD in the peripheral blood progenitor cell (PBPC)
leukapheresis product of patients undergoing autoHCT for
ALL would predict the risk of post-transplantation relapse.
Alternatively, patients conventionally considered high-risk
but who achieve an MRD-negative state as quantiﬁed by
NGS might potentially be cured by a non-alloHCT approach.
The ability to identify such patients may be useful for the
management of those at high risk for treatment-related
mortality (TRM) from alloHCT and of those without optimal
alloHCT donors available.
In this study, we retrospectively applied an NGS platform
to assess clonality at the IGH locus (complete IGH-VDJ rear-
rangements and partial IGH-DJ rearrangements), the IGK
locus, and the TCRB, TCRD, and TCRG loci, in the diagnostic
specimens of adult patients with B-ALL and T cell ALL who
underwent autoHCT. The leukemia-associated Ig/TCR
clonotypes were then quantiﬁed in cryopreserved PBPC
leukapheresis samples, and correlations between disease
burden and clinical outcomes were evaluated. We addition-
ally sought to determine the impact of ex vivo graft purging
on MRD levels, as well as the correlation between peripheral
blood BCR-ABL transcripts and autograft disease burden as
measured by NGS in Phþ patients.
PATIENTS AND METHODS
Study Subjects
Between March 1990 and February 2014, 48 adult ALL patients (ages, 19
to 55 years) underwent autoHCT at the University of California, San Fran-
cisco (UCSF) Medical Center. Of these, 32 (67%) patients were eligible for this
study based on having both an archived, disease-bearing diagnostic sample
to evaluate for clonal Ig/TCR rearrangements as well as an archived PBPC
leukapheresis sample to evaluate for MRD. We reviewed the demographic
and clinical variables of these patients, with information obtained via 2
electronic medical record systems as well as via physical chart review. To
ensure accurate dates of death, the UCSF Cancer Center registry was
accessed, in addition to 2 publicly available online death indicesdthe Social
Security Death Index (1935 to 2014) and the California Death Index (1940 to
1997). Patients whose clinical status remained unknown after searching
these registries were contacted by telephone. Data was censored on
September 1, 2015. The study was approved by the UCSF Committee on
Human Research.
AutoHCT
Of the 32 patients evaluated, 7 patients (22%) participated in a multi-
institutional clinical trial evaluating an intensiﬁed approach to autoHCTfor patients with high-risk ALL, as deﬁned by B lineage disease with WBC
count at diagnosis >30,000/uL; high-risk cytogenetics, including t(9;22),
t(4;11), other 11q23 abnormalities, or monosomy 7; or failure to achieve CR
after a ﬁrst course of consolidation chemotherapy [15]. Peripheral he-
matopoietic cell mobilization consisted of cytarabine 2000 mg/m2 i.v. every
12 hours for 8 doses (16,000 mg/m2 cumulative) on days 1 to 4 and eto-
poside 40 mg/kg cumulative by continuous i.v. infusion on days 1 through 4.
Granulocyte colonyestimulating factor 10 mcg/kg was given subcutane-
ously from day 14 until hematopoietic cell collection, which was begun
when theWBC count exceeded 5000/uL. For patients with B lineage disease,
ex vivo complement-mediated purging was performed via monoclonal
antibodies against CD9, CD10, CD19, and CD20, and for patients with
T lineage, against CD2, CD3, CD4, CD5, and CD8. The pretransplantation
conditioning regimen consisted of high-dose total body irradiation given in
11 fractions of 120 cGy each, for a total dose of 1320 cGy from days8 to5.
Etoposide 60 mg/kg was given on day4 and cyclophosphamide 100 mg/kg
was given on day 2. TKIs were permitted for all patients with Phþ ALL.
The remaining 25 patients who were not treated on study met similar
criteria for high-risk disease and underwent the same stem cell mobilization
and pretransplantation conditioning protocol, but without ex vivo purging
of the PBPC graft.
MRD Quantiﬁcation
PBPC from patients undergoing leukapheresis were retrieved from
liquid nitrogen vapor cryopreservation, thawed, and washed. Genomic DNA
was isolated from cells using a DNeasy kit (Qiagen, Valencia, CA) according
to the manufacturer’s instructions. Genomic DNA samples were then
processed as described elsewhere [23]. Brieﬂy, using the immunoSEQ NGS
platform (Adaptive Biotechnologies Corp, South San Francisco, CA), rear-
ranged immunoreceptor loci from genomic DNA samples were ampliﬁed
and sequenced using V and J segment consensus primers for each gene
(IgH, IgK, TCRB, TCRD, and TCRG) and, in some cases, D segment primers for
incomplete IGH-DJ rearrangements [21].
Sequences were analyzed using standardized algorithms for clonotype
determination [22]. Leukemia-speciﬁc clonotypes were identiﬁed for each
patient, based on their high prevalence in a marrow sample at a time of high
disease burden. MRD levels were then determined in PBPC and quantiﬁed
using spiked-in reference sequences in the reaction mixture to permit
control for oversequencing, thus enabling reporting of absolute clonotype
frequency (reported as leukemia clonotypes per million leukocyte
genomes).
Deﬁnition of Outcomes
We deﬁned RFS as the time from graft infusion (day 0) to relapse, which
was determined by standard diagnostic criteria. Overall survival (OS) was
deﬁned as the interval between graft infusion and death from any cause.
Statistical Analysis
Continuous data are reported as mean ( SD) and time data are reported
as median (range). Categorical data are reported as frequency (%). Kaplan-
Meier curves were generated using GraphPad Prism (GraphPad Software,
La Jolla, CA) and statistical differences assessed via log-rank and Wilcoxon
analyses, with a P value of <.05 considered signiﬁcant. Multivariate analysis
was performed via the stepwise regression method under logistic models
using SAS 9.4 (SAS Institute, Inc Cary, NC).
RESULTS
Patient and Sample Characteristics
Thirty-two ALL patients who underwent autoHCT were
considered for this retrospective study. Of these, 4 (13%)
patients had diagnostic bone marrow aspirate samples
that yielded insufﬁcient DNA to be assessed for leukemia-
associated Ig/TCR clonotypes and were, therefore, unavai-
lable for MRD assessment. Of the remaining 28 evaluable
patients, 12 (38%) patients had Phþ B-ALL, 12 (38%) had Ph
B-ALL, and 4 (14%) had T cell ALL (Table 1). The majority of
patients were male, in ﬁrst CR, and autografted in the decade
between 2000 and 2009. Of the Phþ cohort, 2 patients
(16.7%) additionally had hyperdiploid cytogenetics and
1 patient (8.3%) harbored monosomy 7. Of the Ph cohort,
7 patients (58%) had diploid cytogenetics, 2 patients (16.7%)
harbored a t(4;11), and 3 patients (25%) harbored other
miscellaneous chromosomal abnormalities.
Table 1
Patient Characteristics
Characteristic Entire Cohort Phþ Cohort Ph Cohort T Cell Cohort
No. of patients 28 (100) 12 (42.9) 12 (42.9) 4 (14.3)
Male sex 19 (67.8) 6 (50) 9 (75) 4 (100)
Age at autoHCT, median (range), yr 32 (19-55) 35 (23-55) 33 (22-49) 25 (19-45)
Remission status at autoHCT
CR1* 19 (67.9) 10 (83.3) 7 (58.3) 2 (50)
CR2 8 (28.6) 1 (8.3) 5 (41.7) 2 (50)
Treatment era
Pre-2000 8 (28.6) 2 (16.7) 4 (33.3) 2 (50)
2000-2009 17 (60.7) 9 (75) 6 (50) 2 (50)
2010-Present 3 (10.7) 1 (8.3) 2 (16.7) 0 (0)
Ex vivo purging of grafts 7 (25) 2 (16.7) 4 (33.3) 1 (8.3)
Length of post-autoHCT follow-up, median (range), mo 41.0 (3-217) 41.6 (3-165) 41.0 (9-217) 48.6 (9-91)
Data presented are n (%), unless otherwise indicated.
* One patient in the Phþ cohort had MRD detectable by BCR-ABL PCR.
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median RFS and OS for the entire cohort were 3.2 and
4.2 years, respectively; at 5 years after transplantation, 42%
of patients remain alive and relapse free (Figure 1A). RFS and
OS for the Phþ, Ph, and T cell ALL subgroups are shown in
Figure 1B-D.
Identiﬁcation of Ig and TCR Locus Rearrangements
Of the 28 diagnostic specimens, 100% of patients had
leukemia-associated Ig/TCR clonotypes amenable to quantiﬁ-
cation by NGS. Seven patients (25%) had rearrangements in 1
immunoreceptor locus (Figure 2A), whereas 21 (75%) had
rearrangements in 2 ormore immunoreceptor loci (range, 2 to
7). A total of 73 rearrangements were identiﬁed across all pa-
tients. Clonal IGHsequenceswithcompleteVDJ rearrangementFigure 1. Relapse-free survival (RFS) and overall survival (OS) for patients who under
the Phþ B-ALL cohort, (C) RFS and OS for the Ph B-ALL cohort, and (D) RFS and OSwere the most commonly identiﬁed clonal marker, present in
17of 28patients (61%,17 of 24with B-ALL) and representing 30
of the 73 (41%) total rearrangements (Figure 2B). Other
immunoreceptor loci exhibiting clonality included TCRG in
15 (54%) patients (25% of the total rearrangements), TCRD
in 8 (29%) patients (11% of the total rearrangements), IgK
in 7 (25%) patients (9.6% of the total rearrangements), IgH-DJ
in 5 (18%) patients (6.8% of the total rearrangements), and
TCRB in 3 (11%) patients (4.1% of the total rearrangements).
Effect of Ex Vivo Purging
Seven patients (25%) received autografts that had under-
gone ex vivo complement-mediated purging, 3 (43%) of whom
haddetectableMRD byNGS. One patient had Phþ B-ALL,1 had
PhB-ALL, and1hadTcell ALL. The clonotype frequency in thewent autoHCT for ALL. (A) RFS and OS for the entire cohort, (B) RFS and OS for
for the T cell ALL cohort.
Figure 2. Frequency of immunoglobulin and T cell receptor loci rearrange-
ment detection in diagnostic samples. The number of leukemia-associated
immunoreceptor locus rearrangements per patient is shown in (A). For each
of the immunoreceptors tested, the frequency of clonotypes in diagnostic
specimens is shown in (B).
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Figure 3. Two of the 3 patients each harbored 1 clone, whereas
the third patient harbored 7 clones. Paradoxically, 7 of the 9
total clones (78%) increased after the purge. All 3 of these pa-
tients who had detectable MRD ultimately relapsed. The Phþ
patient (patient number 10) underwent autoHCT before the
widespread use of TKIs butwas BCR-ABL negativewhen tested
within 90 days before transplantation.
Prognostic Value of Pre-AutoHCT MRD Quantiﬁcation
Using a threshold of  106 for MRD detection, median
RFS for patients with detectable MRD (n ¼ 13) wasFigure 3. Effect of ex vivo purging using CD9, CD10, CD19, and CD20 monoclonal an
T-ALL on MRD in peripheral blood progenitor cell leukapheresis products of 3 patien6.5 months and was not reached for patients without
detectable disease (n ¼ 15) above this threshold (P ¼ .0005)
(Figure 4). If any level of MRDwas considered positive, which
included 3 patients with clones that were detected at 106
(speciﬁcally at 2  107, 7  107, and 8  107), median RFS
for MRD-positive and MRD-negative patients was similar to
the median RFS measured when the threshold of 106 was
used (6.5 months versus not reached, respectively, P ¼
.0004). In multivariate analysis including age, sex, disease
group, remission status at time of autoHCT, and MRD status,
the presence of MRD above the threshold of 1106 was the
only signiﬁcant independent predictor of relapse (odds ratio,
23.8; conﬁdence interval, 1.8 to 312.9; P ¼ .0158).
When stratiﬁed according to Phþ B-ALL, Ph B-ALL, or
T cell ALL, a statistically signiﬁcant difference was seen only
in patients with Ph- B-ALL, though all subsets showed a trend
toward improved RFS for patients in molecular remission (ie,
MRD undetectable) (Supplementary Figure 1A-C).
Two patients with detectable MRD above the 1  106
threshold did not relapse (“false positives”) (Supplementary
Table 1). One of these patients died from TRM 3months after
transplantation, and 1 patient had Phþ B cell ALL and was
treated with a TKI after transplantation. Of the 4 patients
who relapsed despite not having MRD above the 1  106
threshold (“false negatives”), 2 had detectable MRD below
the 1  106 threshold (Supplementary Table 2).BCR-ABL PCR versus NGS for Phþ ALL
Of the 12 patients with Phþ B-ALL, 7 (58%) had docu-
mented PCR testing for the BCR-ABL transcript within
90 days before autoHCT (Table 2). Only 1 of the patients who
underwent testing had detectable BCR-ABL transcript (weak
positive) before transplantation. Interestingly, this patient
did not have detectable MRD via the NGS assay. This patient
received a TKI after autoHCT and is relapse free with >
5 years of follow-up. Of the remaining 6 Phþ B-ALL patients
with undetectable BCR-ABL by PCR, 4 (67%) had detectable
disease using NGS.
Ten (83%) patients were treated with a TKI after autoHCT.
The 2 patients who did not receive a post-transplantation TKI
both diedwithin 6months,1 from transplant-related toxicity
and the other from leukemia relapse. Four (40%) of the 10
patients treated with a TKI after transplantation had
detectable MRD by NGS in their leukapheresis product. Two
(50%) of these patients relapsed, whereas 2 (50%) remain
long-term relapse-free survivors. Of the 2 patients with
MRD who relapsed despite being on a TKI, 1 harboredtibodies for B-ALL or CD2, CD3, CD4, CD5, and CD8 monoclonal antibodies for
ts with detectable MRD whose leukapheresis product underwent purging.
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Figure 4. Relapse-free survival (RFS) for the entire cohort, stratiﬁed by min-
imal residual disease (MRD) status. Using a threshold of detection of 106,
MRD-negative patients experience signiﬁcantly improved RFS, with the
median not reached for MRD-negative patients and 6.5 months for
MRD-positive patients (P ¼ .0005).
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high-risk features and relapsed within 6 months after
autoHCT despite treatment with imatinib. Of the 6 Phþ pa-
tients treated with a post-transplantation TKI who had no
detectable MRD via NGS, only 1 (17%) patient relapsed,
occurring 12 months after transplantation. Median RFS for
the other 5 patients is 135 months (range, 19.1 to
157 months).
Of the 6 patients with more than 5 years of follow-up, 2
(33%) discontinued TKI therapy (at 7 and 8 years after
autoHCT), and both remain alive and relapse free at 13 and
14 years after autoHCT, respectively.DISCUSSION
Routine MRD assessment has become an essential
component of ALLmanagement, with the persistence ofMRD
after initial therapy strongly correlating with the risk of
relapse in both children and adults [9,20,24-27]. Deter-
mining how the presence of MRD should inform subsequent
risk-adapted clinical decision-making, however, remains
poorly deﬁned. In this study, we demonstrate that an NGS
platform can identify MRD in the leukapheresed autografts
of patients who undergo autoHCT for ALL and that theTable 2
Characteristics and Clinical Outcomes of Patients with Phþ ALL Undergoing AutoH
Patient No. Age at
HCT, yr
Remission
Status
Year of
HCT
BCR-ABL
Positive
HTS MRD
Positive
1 23 CR1 1990 NA Y
10 30 CR1 1999 N Y
13 32 CR1 2001 N Y
14 42 CR1 2002 NA N
16 25 CR2 2003 N Y
17 43 CR1 2003 NA N
18 37 CR1 2004 NA N
19 27 CR1 2004 N Y
20 49 CR1 2004 NA Y
26 55 CR1 2008 Y N
28 26 CR1 2008 N N
34 52 CR1 2013 N N
HTS indicates high-throughput sequencing; NA, not available; Y, yes; N, no; CNS,presence of detectable leukemia clonotypes in the autograft
strongly predicts relapse. Perhaps more importantly, the
absence of MRD may identify a subset of high-risk patients
who are able to achieve long-term remission without being
exposed to the TRM risk of alloHCT. Additionally, we add to
the growing body of evidence that TKI therapy for patients
with Phþ B-ALL may, in some cases, abrogate the need for
alloHCT [28].
MRD assessment via the NGS platform has now been
validated as a powerful diagnostic and prognostic tool across
multiple diseases, including ALL, diffuse large B cell lym-
phoma, Hodgkin lymphoma, chronic lymphocytic leukemia,
and myeloma [21,29-37]. Although autoHCT is not a standard
therapy for ALL, this study serves as proof of principle that
the presence of MRD as determined by NGSdeven when
extrapolated to the setting of autologous PBPC graftsdhas an
adverse impact on outcomes and that a deep, molecular
remission has highly favorable prognostic signiﬁcance.
Despite the small sample size in our study, MRD detected at a
threshold of 106 in the PBPC grafts clearly stratiﬁed pa-
tients into groups at either high or low risk for relapse.
A similar retrospective analysis from the European Leukemia
Net’s Study Group on Adult ALL was performed in patients
with ALL who underwent autoHCT using pretransplantation
peripheral blood MRD assessment via either multiparameter
ﬂow cytometry or PCR. In a multivariate analysis adjusted for
other potential prognostic factors, MRD in peripheral blood
was the only independent factor associated with increased
risk of relapse (risk ratio, 2.8; P ¼ .0005).
Our study used a highly sensitive and speciﬁc NGS
method for MRD quantiﬁcation, which has some potential
advantages over both ﬂow cytometry and traditional quan-
titative PCR (Q-PCR), including the ﬂexibility to use
cryopreserved graft samples, which are suboptimal for ﬂow
cytometric quantiﬁcation of MRD. Additional beneﬁts
include deeper detection limit with NGS (sensitive to 106 to
107 clonotype detection), whereas ﬂow cytometry is typi-
cally limited to 103 to 104 sensitivity and Q-PCR is gener-
ally limited to 104 to 105 sensitivity [23]. Several studies
comparing NGS to these other technologies have demon-
strated the ability to detect MRD in specimens deemed MRD
negative by ﬂow/Q-PCR [23,28,38,39]. An additional beneﬁt
of the NGS approach is the use of consensus primer and
multiplexed PCR, such that no patient-speciﬁc PCR reagents
are required, as is the case for Q-PCR [23,28,38].
For patients who are MRD negative before autoHCT, the
unanswered question is whether autoHCT offers any beneﬁtCT
Post-HCT
TKI
Relapse RFS, mo Notes
N N 3 Died from transplantation
toxicity
N Y 3
Y N 165 Stopped TKI after 8 yr
Y N 157 Stopped TKI after 7 yr
Y N 69
Y N 135
Y N 135
Y Y 4 Monosomy 7
Y Y 7
Y N 64 “Weak positive” PCR
Y Y 12 CNS involvement
Y N 19
central nervous system.
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ALL patients, over TKI therapy, either with or without
chemotherapy. It has already been established that MRD
negativity at the end of induction chemotherapy portends a
favorable prognosis with prolonged intensiﬁcation and
maintenance chemotherapy, but the signiﬁcance of
achieving MRD negativity only later in the course of
chemotherapy remains largely unknown. Identiﬁcation of
patients likely to be cured by autoHCT may be useful because
of the substantially shortened course of medical therapy
needed with autoHCT versus prolonged intensiﬁcation and
maintenance therapy. Additionally, alloHCT is not feasible for
many patients, so the ability to select patients with high
potential to maximize long-term RFS using autoHCT is
clinically useful. Nonetheless, with the recent advent of
bispeciﬁc T cell engager antibodies, such as blinatumomab,
as well as the emerging ﬁeld of chimeric antigen receptor
T cells, the future role of autoHCT for ALL is unknown
[40-44]. It is worth additional study to determine whether
autoHCT for patients in remission may improve outcomes for
those who subsequently receive immunologic consolidation
of deep molecular remission with 1 of these approaches.
Our study assessed MRD in the PBPC apheresis product
used for autoHCT. It remains unknown whether MRD
assessment before a chemo-mobilization for stem cell
collection would supplant the need to assess the stem cell
product for disease burden. It seems clear, however, that
autoHCT with stem cell products bearing 106 leukemic
burden are of limited clinical utility and should not be pur-
sued outside of a clinical trial. Though we had few specimens
from patients receiving purged autografts, our ﬁndings
further demonstrate that ex vivo purging with monoclonal
antibodies to lymphoid antigens does not eradicate leukemia
MRD from PBPC products. For patients who are MRD positive
after the completion of initial therapy, it seems likely that
novel therapies, such as bispeciﬁc T cell antibodies and
chimeric antigen receptor T cells, may soon be able to over-
come the adverse prognostic impact of MRD positivity.
Finding an approach to therapy that minimizes potential
toxicities is particularly important in the subset of patients
with Phþ ALL, as targeted therapy is available for their ma-
lignancy. Interestingly, our study found that despite detect-
able MRD in the PBPC leukapheresis product, 2 of 4 patients
treated with autoHCT and post-transplantation TKI were
long-term, relapse-free survivors. Whether their survival is
attributable to having received an autoHCT, a TKI, or both is
unknown. Also of note, 2 patients ultimately discontinued TKI
therapy and have each remained relapse-free for more than 5
and 7 years after stopping all leukemia-directed therapy.
Unlike several recent and ongoing studies in chronic myeloid
leukemia, there are currently no clear data to inform the
optimal duration of TKI therapy in Phþ ALL [45,46].
This study has several limitations, most notably its
retrospective nature and relatively small sample size.
Accordingly, we were unable to evaluate pretransplantation
peripheral blood samples or marrow aspirates to determine
of whether MRD levels in peripheral blood or marrow aspi-
rates could serve as a surrogate for the disease burden we
measured in the PBPC leukapheresis product. Because only
32 of 48 (67%) of the ALL patients treatedwith autoHCTat our
institution were evaluable based on specimen availability,
there is the potential for selection bias. Finally, statistical
power for analysis according to disease subclassiﬁcation was
limited because of the sample size. Nonetheless, this cohort
represents a relatively unique and homogeneously treatedgroup of patients with high-risk disease, demonstrating for
the ﬁrst time that MRD in the PBPC leukapheresis product of
patients with ALL predicts relapse risk.
Although the role of autoHCT in the treatment of ALL
remains unclear, the ﬁndings of this study support ongoing
efforts to prospectively study risk-adapted, MRD-based
strategies for the treatment of adult ALL. Novel agents such
as blinatumomabdused to reduce MRD burden before stem
cell collectiondmay prove to be particularly useful in com-
bination with an “intensiﬁed” autoHCT for ALL, thereby
providing a potential alternative to either alloHCT or to the
prolonged intensiﬁcation and maintenance approaches
currently used with conventional chemotherapy.
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